Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Now accepting nominations for the Fierce Innovation Awards - Submit your application today
MariTide
Biotech
Amgen drops ph. 1 obesity drug, upping pressure on MariTide
The now-canned AMG 513 was previously hit with a clinical hold by the FDA in February 2025, which was lifted a few months later.
Darren Incorvaia
Aug 4, 2026 4:01pm
Fierce Pharma
Obesity meds, China drive $2T in projected 2032 drug sales: report
Jun 23, 2026 9:00am
Amgen's ph. 3 MariTide studies will ramp up dosing to quell nausea
Jun 24, 2025 9:59am
Amgen’s late-stage obesity trials expected to read out in ‘27
Mar 5, 2025 1:58pm